During heart failure (HF), the left ventricle (LV) releases B-type natriuretic peptide (BNP), possibly contributing to adverse cardiovascular events including ventricular arrhythmias (VAs) and LV remodelling. We investigated the cardiac effects of chronic BNP elevation in healthy mice and compared the results with a model of HF after myocardial infarction (PMI mice).
Introduction
B-type natriuretic peptide (BNP) is synthesized in cardiac myocytes and released in excess into the blood circulation following left ventricular (LV) wall stretching. 1 During the onset of ventricular remodelling after myocardial infarction (PMI), BNP is chronically elevated and is a strong indicator of heart failure (HF) severity. 1 Despite favourable haemodynamic effects, high blood BNP is associated with the risk of ventricular arrhythmias (VAs) and sudden cardiac death (SCD). 2, 3 Consequently, the effectiveness of therapies aimed at increasing BNP during HF is still questionable. 4 While short-term BNP infusion is of haemodynamic benefit, with natriuretic, diuretic, and vasorelaxant effects, chronic BNP treatment increases the risk of mortality. 3, 5, 6 Sympathetic activation related to a reflex response triggered by these haemodynamic effects could be implicated in this process. 7, 8 Although the signalling pathways mediating the effects of BNP are poorly understood, a therapeutic strategy that could prevent the deleterious effects of BNP without affecting its benefits remains of interest. Altered Ca 2+ cycling, characterized by increased sarcoplasmic reticulum (SR) Ca 2+ leak, decreased SR Ca 2+ uptake leading to diastolic Ca 2+ elevation, and decreased systolic Ca 2+ levels, is a common feature in chronic HF. 9 -11 Such altered Ca 2+ -handling and chronic sympathetic overdrive are established components of chronic HF triggering VA. 12 BNP decreases the expression of SR Ca 2+ ATPase 2a (SERCA2a) 13, 14 and induces pro-adrenergic effects. 15 We thus hypothesized that BNP could influence two key players in the triggering of VA and, more globally, in cardiac remodelling during HF. Our present study attempts to determine the effect of chronic BNP treatment on LV function both in vivo in healthy mice and at the cellular level. Here, we show, by heart rate variability (HRV) analysis and the use of the b-blocker metoprolol, that increased sympathetic tone associated with Ca 2+ -handling alterations contributes to BNP-mediated LV remodelling and VA.
Methods

Animals and BNP
All procedures conformed to European Parliament Directive 2010/63/EU and the 22 September 2010 Council on the protection of animals and were approved by the local institutional animal research committee (Languedoc Roussillon, No. CE-LR-0714).
For cardiomyocyte experiments, the heart was explanted after euthanasia by cervical dislocation. Seven-week-old male C57BL/6 mice (Janvier, Le Genest-Saint-Isle, France) were randomly assigned to the following groups: (i) Sham; (ii) Sham treated with BNP (BNP-Sham); (iii) mice subjected to HF by left coronary artery ligation (PMI); (iv) BNP-Sham mice treated with the b1-adrenergic blocker metoprolol (BB-BNP-Sham); and (v) PMI mice treated with metoprolol (BB-PMI). For PMI, a left thoracotomy was performed under anaesthesia and cardiac monitoring (2% isoflurane/O 2 , Aerrane w , Baxter, France). The artery was ligated 1 -2 mm beyond its point of emergence from the top of the left atrium, using an 8-0 suture. A subcutaneous injection of 0.01 mL buprenorphine solution (0.3 mg/mL) was administered for post-operative analgesia. Sham mice were subjected to the same surgical procedure but without coronary artery ligation. Two mice died during surgery, i.e. before their inclusion in the study, and were replaced. Metoprolol (Sigma-Aldrich, 100 mg/kg/ day) was administered in the drinking water. The dose was determined based on the literature. In the range of 60 -350 mg/kg/day, metoprolol has beneficial effects on cardiac and cellular function. 16 -20 Here, the dose of 100 mg/kg/day reduced the heart rate and improved the HRV parameters in PMI mice without affecting the water intake. Mouse BNP(1-45) (Ref 14-5-30A, American Peptide, Sunnyvale, CA, USA) was administered to Shams at a rate of 0.03 mg/kg/min for 14 days, using a micro-osmotic pump (Alzet 1002, Charles River, France), to achieve plasma BNP levels similar to the steady-state level observed in PMI mice. Circulating BNP levels were measured in duplicate using a commercial kit (Phoenix Pharmaceuticals, Belmont, CA, USA). The timeline of experiments is shown in the Supplementary material online, Figure S1 .
Histology
Haematoxylin-eosin and Sirius red staining were performed as described. 21 Results indicate the area of Sirius red-stained tissue as a percentage of the total area of myocardial tissue.
In vivo analysis
Cardiac function was assessed by echocardiography (Vivid7Pro, GE Medical Systems, USA 
Statistical analysis
All data are reported as means + standard deviation. Statistical analyses were performed using GraphPad Prism and Origin Softwares. One-way ANOVA for multiple comparisons was used, followed by a parametric t-test with Bonferroni's correction for all parameters. A P-value of 0.05 or less indicated a statistically significant difference.
Results
Plasma BNP levels in BNP-Sham and PMI mice
Sham mice had levels of circulating BNP lower than the detection limit (,0.34 ng/mL). In PMI mice, BNP increased to 5.4 + 1.2 ng/mL (n ¼ 8) 14 days after MI and remained stable over the next 2 weeks. At week 4, BNP-Sham mice presented BNP levels (6.8 + 1.4 ng/mL, n ¼ 8) similar to those measured in PMI animals (5.1 + 0.9 ng/mL, n ¼ 7).
Morphofunctional and electrocardiographic effects of BNP
Chronic BNP treatment increased the heart weight -body weight ratio (HWR) of BNP-Sham and PMI mice ( Table 1) . Unlike modifications in PMI mice, echocardiography revealed an unchanged LVEDd and SF in BNP-Sham mice ( Table 1) . ECG showed an unchanged heart rate in BNP-Sham mice, whereas it was increased in PMI mice as indicated by the decreased RR interval ( Figure 1A ). The PR interval, corresponding to the conduction time from the sinus node through the atrioventricular (AV) node to the ventricle, was unaltered in both BNP-Sham and PMI mice ( Figure 1A ), whereas the QRS duration, representing the time to ventricular depolarization and early repolarization, was lengthened in PMI mice ( Figure 1C ). In addition, multiple spikes within the complex (fragmented QRS), 22 probably caused by myocardial scarring, were observed in PMI but not in BNP-Sham mice. The QTc interval was increased in both BNP-Sham and PMI mice ( Figure 1D ). ECG analyses showed that chronic BNP treatment did not alter electrical conduction. In accordance with this finding, BNP had no effect on fibrosis as quantified by collagen content, whereas a large increase was observed in PMI mice ( Table 1) .
Effect of BNP on cardiac sympathovagal regulation
We examined the regulation of the cardiac rhythm by the autonomic nervous system (ANS) by examining the HRV. 10, 21, 23, 24 The HRV, assessed by the standard deviation of the mean of all normal sinus intervals (SDNN), was comparably decreased in BNP-Sham and PMI mice ( Figure 1E) , suggesting an elevation of sympathetic tone. 23, 24 Frequency-domain analysis showed that oscillations in 'low'-frequency bands (LF), reflecting parasympathetic and sympathetic components, were increased in BNP-Sham mice ( Figure 1F) , whereas 'high'-frequency oscillations (HF), reflecting exclusively vagal activity, were unchanged ( Figure 1G ). The increase in the LF bands in BNP-Sham mice is consistent with increased sympathetic activity without a detectable modification of the mean heart rate. 25 The typical profile of HRV parameters measured in PMI mice, with a blunted LF band and LF/HF ratio ( Figure 1F-H) , confirmed the loss of rhythmicity of ANS activity on the heart and the severity of cardiac pathology in PMI animals. 24, 26, 27 This blunting could result from the saturating influence of persistent high sympathetic tone on the sinus node 24 (as attested by the decreased RR interval), or from an impairment of b-adrenergic receptor signalling following chronic sympathetic activation.
26,27
BNP promotes rhythm disorders
Mice, like humans, display spontaneous arrhythmias (Figure 2A-C) . Sham, BNP-Sham, and PMI mice exhibited comparable incidences of sinus arrests ( Figure 2D ) and AV blocks ( Figure 2E ). In contrast, more VAs were observed in BNP-Sham and PMI than in Sham mice ( Figure 2F ). Ventricular tachycardia (VT, defined as more than five consecutive ectopic beats; Figure 2G ) was observed in BNP-Sham (2/8 mice) and PMI (3/12) but not Sham mice (0/12).
Preventive effect of the b-blocker metoprolol
The influence of the BNP-induced neurohormonal imbalance on the ANS was further investigated using the b1-adrenergic blocker metoprolol. Metoprolol reduced the heart rate, as shown by the increased RR ( Figure 1A ) and PR intervals ( Figure 1B ) in BB-BNP-Sham and BB-PMI mice. It had no effect on QRS lengthening either in BB-BNP-Sham, or in BB-PMI mice, as would be expected from the structural alterations (fibrosis) in PMI mice ( Figure 1B) . In addition, myocardial collagen deposits were unchanged in BB-BNP-Sham when compared with BNP-Sham mice (0.2 + 0.0, n ¼ 7 vs. 0.2 + 0.0%, n ¼ 4) and in BB-PMI when compared with PMI mice (4.4 + 1.9, n ¼ 7 vs. 5.2 + 1.8%, n ¼ 4), consistent with a previous study. 28 Metoprolol had a weak effect on morphofunctional parameters such as LVEDd (26.6 + 0.4 and 39 + 0.6 mm) and SF (60.1 + 4.6 and 22 + 2.2%, respectively, in BB-BNP-Sham and BB-PMI mice, n ¼ 5 each). However, metoprolol decreased the QTc in both BB-BNP-Sham and BB-PMI mice ( Figure 1D) .
Metoprolol also abolished the decrease in the SDNN in both BB-BNP-Sham and BB-PMI mice ( Figure 1E ). In the frequency domain, metoprolol decreased the LF in both BB-BNP-Sham and BB-PMI mice ( Figure 1F) , without modifying the HF ( Figure 1G) . Overall, metoprolol prevented the sympathovagal imbalance observed both after BNP treatment and in PMI mice ( Figure 1H) . Metoprolol also reduced premature ventricular contractions (PVC) both in BB-PMI and BB-BNP-Sham mice ( Figure 2F) . No VT was observed with metoprolol, but two of eight BB-BNP-Sham and one of eight BB-PMI mice presented a high incidence of sinus arrests and AV blocks (first degree), in line with the slowing of the AV conduction time by metoprolol. 29 
BNP promotes alterations in Ca 21 handling
The detection of VAs in the absence of conduction disorders or fibrosis led us to investigate the cellular mechanisms underlying the pro-arrhythmogenic effect of BNP in single LV cardiomyocytes. First, we found that both BNP and MI increased cell size. BNP increased the cell volume ( Table 1 ) and cell length when compared with Shams, consistent with cell hypertrophy, which was prevented by metoprolol (data not shown). We next measured intracellular Ca 2+ transients using Fluo-4 AM ( Figure 3A-F) and Indo-1 AM ( Figure 4A-C) . In BNP-Sham and PMI mice, the amplitude of Ca Figure 4D . Both BNP-Sham and PMI cells exhibited more Ca 2+ sparks, with lower amplitudes, than
Sham cells, a change prevented by metoprolol ( Figure 4E and F ) .
BNP decreases SERCA2a and S100A1 expression
Although SR Ca 2+ leak reduces SR Ca 2+ content and cell shortening, it does not explain the slowing of Ca 2+ transient decay kinetics, known to result mainly from Ca 2+ reuptake into the SR via SERCA2a, and Ca 2+ extrusion by the Na + /Ca 2+ exchanger (NCX1). SERCA2a activity is inhibited by PLB, and PLB phosphorylation (P-PLB) relieves this inhibition. 12 SERCA2a activity is also modulated by the small Ca 2+ -binding protein S100A1. 30 Here, we found reduced SERCA2a and S100A1 protein expression in the LV of BNP-Sham mice ( Figure 5A and C ), with no modification of PLB or the P-PLB/PLB ratio ( Figure 5D-F) . RyR protein content was decreased ( Figure 5G ), whereas the Pser 2809 RyR/RyR ratio remained constant ( Figure 5H and I ). NCX1 protein content was increased ( Figure 5B) . In PMI mice, the results were similar overall, notably regarding SERCA2a, NCX1, and S100A1. However, the P-PLB/PLB ratio was decreased ( Figure 5D-F) , and the Pser 2809 RyR/RyR ratio was increased ( Figure 5G-I) . Metoprolol had substantial beneficial effects on both BB-BNP-Sham and BB-PMI mice by preventing the reduction in SERCA2a and S100A1 and the increase in NCX1, and by increasing the P-PLB/PLB ratio ( Figure 5A-F) . Metoprolol also decreased the Pser
2809
RyR/RyR ratio in BB-PMI mice ( Figure 5G-I ).
Discussion
In the present study, we show that in healthy mice, circulating BNP, at levels consistent with those measured during HF following MI, severely alters cellular and molecular functions in cardiomyocytes. role for the sympathetic nervous system in the cardiac effects of circulating BNP.
High blood BNP levels promote Ca 21 waves and VA in healthy mice
A striking finding was that chronic exposure of the heart to high BNP levels promoted PVC, consistent with the correlation between high BNP levels and VA and SCD in HF patients. 2 VA occurred in the absence of fibrosis, in line with the normal QRS duration, and was associated with mechanisms intrinsic to LV cardiomyocytes and consistent with the participation of spontaneous diastolic Ca 2+ waves.
The accumulation of aberrant RyR openings in diastole, observed functionally by the higher incidence of Ca 2+ sparks, provided the substrate for VA/VT by generating Ca 2+ waves. 9,10 Spontaneous Ca 2+ waves are known to induce a transient inward depolarizing current (I ti ) via NCX activation. 31 The increase in NCX1 protein was also likely to favour cellular arrhythmias.
11 Figure 5 Ca 2+ -handling proteins. Normalized protein content and ratios obtained by western blotting for SERCA2a (A), NCX1 (B), S100A1 (C), PLB (D), P-PLB (E), P-PLB/PLB (F ) RyR2 (G), P-RyR (H ), and P-RyR/RyR (I ). *P , 0.05, **P , 0.01, BNP-Sham/PMI vs. Sham animals; £ P , 0.05 and ££ P , 0.01 for metoprolol-treated vs. untreated animals; n ¼ 8 animals per group. The lack of change of Pser 2809 RyR/RyR and P-PLB/PLB ratios in BNP-Sham mice and the fact that neither PKA nor CaMKII is involved in the regulation of RyR and PLB by S100A1 36 together suggest that phosphorylation is not a key player in the chronic effects of BNP. Our data are also consistent with the functional consequences of an S100A1 deficit. 36 Abnormal RyR openings in diastole occurred independently of increased PKA-dependent RyR phosphorylation, known to favour RyR opening. 37 An increase in spark frequency in the absence of increased PKA-dependent RyR phosphorylation is already known. 10 Therefore, the elevation in diastolic Ca 2+ due to impaired SR Ca 2+ uptake may contribute to SR Ca 2+ leak, notably in relation with the biphasic Ca 2+ -dependent effect of S100A1 on RyR activity, which depends on cytosolic Ca 2+ levels. 30, 36 Other mechanisms, such as S-nitrosylation, cannot be excluded. 10 
High blood BNP blunts SERCA2a and S100A1
The role of ANS and the b1-adrenergic pathway
A recent report shows the beneficial effects of local BNP on SERCA2a following intramyocardial gene delivery. 38 This apparent inconsistency with our data, together with other reports, 13 -15 may in fact reflect different aspects of BNP action: localized vs. systemic effects, and/or acute vs. chronic effects. A dose-dependent effect of circulating BNP has been described. 7, 39 Our study points to the critical importance of systemic effects of chronically elevated BNP on cardiac function. Indeed, BNP induces a neurohormonal imbalance and affects the myocardium through sympathetic activation. Decreased HRV is a strong adverse prognostic marker for heart distress and cardiac mortality 40 in patients with decompensated HF 7 or sympathetic overdrive. 24 A decrease in SDNN is an established marker of sympathetic activation in HF, where its reduction parallels disease severity. 24 The increase in the LF and the LF/HF ratio, a sympathovagal index, in healthy mice treated with BNP further confirms enhanced sympathetic tone. 23, 24 This is consistent with findings
showing that high-dose BNP increases sympathetic activity in decompensated HF 7 or in patients with essential hypertension. 8 Overactivation of the sympathetic system is in part responsible for the cellular alterations observed in our model. These effects could result from a reflex response 7, 8 or an enhancement of the adrenergic pathway, 15, 41, 42 which is known to promote ventricular hypertrophy and Ca 2+ -cycling alterations. 43 The use of metoprolol, which counteracts sympathetic overdrive, provides strong evidence for an active role of the b-adrenergic system in the adverse cardiac remodelling induced by chronic BNP. promotes SR Ca 2+ leak by increasing the probability of RyR2 opening, 47 and hampers Ca 2+ reuptake due to reduced SERCA2a activity. 30 Both altered SERCA2a expression and BNP production are considered early indicators of HF and are inversely correlated in human cardiac hypertrophy and HF. 14, 48, 49 Our finding regarding blunted S100A1 and SERCA2a expression in BNP-Sham mice further strengthens the concept that BNP contributes to adverse cardiac remodelling early in the progression of HF. 13, 14 This could explain the ineffectiveness of nesiritide in treating HF, despite its beneficial haemodynamic effects. 15 Both HRV analysis and the prevention of the deleterious effects of BNP by metoprolol suggest that BNP acts in part through adrenergic overdrive. We observed similar effects of metoprolol in BB-PMI mice, confirming previous studies describing an increase in Ca 2+ reuptake through increased SERCA2a expression, increased phosphorylation of PLB, 50 and decreased RyR2 phosphorylation. Our study also highlights the functional consequences of the previously unsuspected but recently described cardiac pro-adrenergic property of BNP, 15 which could potentially lead to a cellular HF-like profile with Ca 2+ -cycling defects or aggravate existing HF.
Clinical implications
Our work shows that elevated blood BNP is not only a biomarker for guided therapy in HF but contributes per se to adverse cardiac remodelling and the triggering of VA, making the rapid lowering of BNP levels in HF patients a highly desirable end, in harmony with early in-hospital treatment aimed at decreasing BNP levels to improve survival. 51 -53 Our study brings into question the treatment of HF patients with synthetic natriuretic peptide-like drugs, whose efficacy is uncertain 54, 55 and whose link to increased mortality has been suspected. 5, 6 Indeed, the ventricular remodelling induced by chronically elevated natriuretic peptides may limit their haemodynamic benefits. Overall, our work supports the general concept that the very early normalization of SERCA2a 56 or/and S100A1 expression 30 is critical in limiting adverse cardiac remodelling in HF. Last, but not least, b-blocker therapy should be considered as soon as BNP levels rise, even in patients without cardiac symptoms.
